Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study

Abstract

Objective and Methods:In order to assess the efficacy of brentuximab vedotin (Bv) in combination with bendamustine (B) in multiple relapsed or refractory (RR) classic Hodgkin lymphoma (cHL), medical records of 47 patients treated with BvB in second relapse or beyond were reviewed. Results:The median number of previous treatments was 2 (1-4). Bv was given at 1.8 mg/kg on day 1 and bendamustine at 90 mg/m 2 on days 1 and 2 of a 21-day cycle. The median number of BvB cycles was 4 (2-7), and all patients were evaluable for efficacy. The CR and OR rates were 49% and 79%, respectively; 67% of responding patients and 2 in stable disease proceeded to a SCT procedure. After a median follow-up of 19 months (5-47), median PFS was 18 months (95%CI: 23-29), and the 2-year OS was 72%. Significantly longer PFS and OS were observed in patients attaining a major clinical response to treatment and in those who received consolidation with SCT. Fifteen (32%) patients experienced severe (G > 2) toxicity. The main toxicities were neutropenia (23%), gastrointestinal (10%), peripheral sensory neuropathy (11%), and infection (4%). Conclusion:Our real-world results suggest that BvB is an effective third-line rescue and bridge-to-transplant regimen for RR-cHL patients.

Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

“…With a median follow‐up of 36 months (range: 8.7–86), in our cohort, the 3‐year OS and PFS are 78.1% and 67%, respectively, these values being comparable to those reported in previous studies on R/R HL children 28,31,37,38,48,51,52 …”

“…The most common treatment‐related AE was grade 3–4 hematological toxicity, which, however, did not cause treatment discontinuation in any patient, but only treatment delay until hematological recovery. Peripheral neuropathy, recorded in 9% of patients, is in line with current evidence in the medical literature and was always reversible 28,37,48 . As the response rate in patients receiving a lower dose of bendamustine (90 mg/m 2 ) was comparable to that of patients given a higher dose of the drug (120 mg/m 2 ), the optimal dosage to be employed in combination with BV remains to be established.…”

“…Peripheral neuropathy, recorded in 9% of patients, is in line with current evidence in the medical literature and was always reversible. 28,37,48 As the response rate in patients receiving a lower dose of bendamustine (90 mg/m 2 ) was comparable to that of patients given a higher dose of the drug (120 mg/m 2 ), the optimal dosage to be employed in combination with BV remains to be established.…”

Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review

“…The use of Bv monotherapy and Bv based regimens in R/R HL has been growing in the last one decade. Table 5 describes some of the significant studies in this setting (17)(18)(19)(20)(21)(34)(35)(36)(37)(38)(39)(40)(41). The combination of BBv has been tested in the developed world in at least 3 prospective trials and more retrospective real-world studies (17-20, 39, 41).…”

“…Peripheral neuropathy and neutropenia were the commonly reported grade III/IV toxicities with an incidence of 10% or more in all the studies. The retrospective studies also used BBv in earlier lines of salvage therapy (first-line or second line salvage) and achieved ORR in the range of 79-92.6% [CR: 49-70.7%] (20,41). Between 67-90% patients in both studies underwent AHCT.…”